(NASDAQ: DNTH) Dianthus Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.32%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.02%.
Dianthus Therapeutics's earnings in 2024 is -$56,681,000.On average, 7 Wall Street analysts forecast DNTH's earnings for 2024 to be -$68,016,895, with the lowest DNTH earnings forecast at -$75,734,146, and the highest DNTH earnings forecast at -$54,011,949. On average, 6 Wall Street analysts forecast DNTH's earnings for 2025 to be -$80,627,511, with the lowest DNTH earnings forecast at -$98,630,515, and the highest DNTH earnings forecast at -$68,102,022.
In 2026, DNTH is forecast to generate -$96,208,784 in earnings, with the lowest earnings forecast at -$131,800,897 and the highest earnings forecast at -$65,460,134.